Ty-Jour T1 - 缺氧负担和心率变异性预测睡眠呼吸暂停中风发病率JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003.04022-2020 SP - 2004022 Au - Blanchard，Margaux Au - Gervès-Pinquié，ChloéAu - Feuilloy，Mathieu Au - Le Vaillant，Marc Au - Tzepizur，Wojciech Au - Meslier，Nicole Au - Goupil，FrançoisAu - Pigeanne，Thierry Au - Balusson，FrédéricAu - Oger，Emmanuel Au - Sabil，Abdelkebir Au - Girault，Jean-Marc Au - Gagnadoux，FrédéricA2 - ，Y1 - 2020 / 01/01/01 UR - //www.qdcxjkg.com/content/early/2020/11/11/13993003.04022-2020.Abstract n2 - 阻塞性睡眠呼吸暂停（OSA）越来越被认为是中风的危险因素[1]。然而，在对OSA调查的患者中卒中的发生率已经在有限数量的研究中进行了评估，报告呼吸暂停症 - 呼吸暂停指数（AHI）和中风发病率之间的关联突破性结果[1-3]。由于OSA是一种非常异质的条件，临床上需要高风险患者的患者亚组的鉴定，以便实施预防措施[1]。基于人口的研究表明，睡眠呼吸暂停特异性缺氧负担（SASHB），来自多核桃摄影（PSG）的容易导出的信号，预测心血管死亡率和事件心力衰竭[4,5]。最近的一项研究表明，夜间心率变异性（HRV）可能在OSA与脑小血管疾病之间的关联中发挥重要作用，这是大量比例的卒中[6]。SASHB和HRV的生理标志物在临床环境中是否有用，用于鉴定那些因脑卒中风险的OSA患者的患者仍有待确定。在对OSA调查的大型多期诊所的患者中，我们假设SASHB和HRV的PSG派生指数可以预测中风入射。最近在欧洲呼吸杂志中被接受的令人挑剔的发布。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Blanchard has nothing to disclose.Conflict of interest: Dr. Gerves-Pinquie has nothing to disclose.Conflict of interest: Dr. Feuilloy has nothing to disclose.Conflict of interest: Dr. Le Vaillant has nothing to disclose.Conflict of interest: Dr. Trzepizur has nothing to disclose.Conflict of interest: Dr. Meslier has nothing to disclose.Conflict of interest: Dr. Goupil has nothing to disclose.Conflict of interest: Dr. Pigeanne has nothing to disclose.Conflict of interest: Dr. Balusson has nothing to disclose.Conflict of interest: Dr. Oger has nothing to disclose.Conflict of interest: Dr. Sabil has nothing to disclose.Conflict of interest: Dr. Girault has nothing to disclose.Conflict of interest: Dr. GAGNADOUX reports grants and personal fees from RESMED, personal fees and non-financial support from SEFAM, personal fees from CIDELEC, personal fees and non-financial support from NOVARTIS, personal fees from ACTELION, non-financial support from BOEHRINGER INGELHEIM, personal fees and non-financial support from AIR LIQUIDE SANTE, non-financial support from ASTEN, outside the submitted work. ER -